Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index; 49 of the 181 sources its claims cite were checked for support.

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Open access

Abstract

Several randomized controlled trials have demonstrated the benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this review, we summarize and discuss the potential mechanisms of stroke protection by GLP-1RAs. GLP-1RAs exert multiple anti-atherosclerotic effects contributing to stroke prevention such as enhanced plaque stability, reduced vascular smooth muscle proliferation, increased nitric oxide, and improved endothelial function. GLP-1RAs also lower the risk of stroke by reducing traditional stroke risk factors including hyperglycemia, hypertension, and dyslipidemia. Independently of these peripheral actions, GLP-1RAs show direct cerebral effects in animal stroke models, such as reduction of infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, blood–brain barrier permeability, and increased neurogenesis, neuroplasticity, angiogenesis, and brain perfusion. Despite these encouraging findings, further research is still needed to understand more thoroughly the mechanisms by which GLP-1RAs may mediate stroke protection specifically in the human diabetic brain.

Overview

CoChat Summary

TL;DR

This comprehensive review summarizes proposed extracerebral and cerebral mechanisms by which GLP-1 receptor agonists may protect against ischemic stroke in type 2 diabetes, including anti-atherosclerotic, risk-factor-lowering, and direct neuroprotective effects. It concludes that animal and clinical evidence is encouraging but still insufficient to fully establish the mechanisms of stroke protection in the human diabetic brain.

Key findings

  • Clinical data consistently associate GLP-1RAs with lower stroke risk: a 2020 meta-analysis of seven CVOTs found 15% lower non-fatal stroke, 19% lower fatal stroke, and 16% lower total stroke; an updated meta-analysis of eight CVOTs found 17% lower fatal or non-fatal stroke; and a retrospective cohort found 29% lower non-fatal ischemic stroke versus DPP-4 inhibitors. Semaglutide showed the highest reported reduction in ischemic stroke risk at 28%, whereas no reduction was reported for short-acting lixisenatide.
  • Extracerebral mechanisms include glycemic, blood pressure, lipid, and anti-atherosclerotic effects: every 1% HbA1c reduction was associated with 41% lower non-fatal stroke risk; in REWIND, HbA1c reduction accounted for approximately 50% and SBP reduction (mean 1.7 mmHg with dulaglutide) for around 14% of the stroke benefit; liraglutide reduced carotid intima-media thickness from 0.97 mm to 0.78 mm at 18 months and reduced soluble CD163 by 22%.
  • In animal stroke models, GLP-1RAs reduced infarct volume, apoptosis, oxidative stress, neuroinflammation, excitotoxicity, and blood–brain barrier permeability, while increasing neurogenesis, neuroplasticity, angiogenesis, and cerebral blood flow; implicated pathways include cAMP/PKA/CREB, PI3K/Akt, MAPK/ERK, Wnt/β-catenin, and Nrf2/HO-1.
  • Human studies support anti-inflammatory and antioxidant effects: a meta-analysis of 40 randomized controlled trials found GLP-1RA therapy reduced CRP and TNF-α and increased adiponectin; exenatide reduced TNF-α, IL-1β, IL-6, serum amyloid A, and MMP-9 in 24 obese patients with T2DM; liraglutide reduced pro-inflammatory cytokines and increased adiponectin.

Methods

  • Narrative comprehensive review of non-clinical and clinical studies evaluating mechanistic effects of GLP-1 and/or GLP-1RAs in preventing ischemic stroke.
  • Evidence synthesized from cardiovascular outcome trials, meta-analyses, retrospective cohort studies, animal models of stroke, and in vitro/ex vivo mechanistic studies.
  • No new primary data or systematic meta-analysis; conclusions are based on narrative synthesis of the available literature.

Limitations

  • Stated: only very limited studies reported negative results on anti-stroke effects, which, along with publication bias, favors positive outcomes; non-clinical studies were mainly in homogeneous rodent models, limiting representation of heterogeneous human stroke; human infarct progression is presumed 2–3 times slower than in rodents; most non-clinical studies used acute ischemic stroke models with drug administration before, during, or after stroke induction, so long-term preventive mechanisms need further investigation; most clinical studies estimated stroke event risk without mechanistic or functional outcomes.
  • Evident: as a narrative review, it does not perform a formal risk-of-bias assessment or quantitative pooling, and it relies heavily on animal models and surrogate endpoints.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12933-022-01686-3

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Potential mechanisms of stroke protection mediated by glucagon-like peptide-1 receptor agonists, with a focus on their intracerebral effects
Fig. 1 Potential mechanisms of stroke protection mediated by glucagon-like peptide-1 receptor agonists, with a focus on their intracerebral effectsCC BY · PubMed Central

Verification

Claims the paper makes

34 Valid · 0 Not valid · 87 Not checked · 15 Own results and interpretations

108 more claims · 25 with their cited sources checked

Create a free account to see all 136 claims and to verify the 132 references still open.

See all claims — free account
  • It may state two separate claims as one. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 101 references

Cited by

See all 72

Metadata

Authors
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P.
Affiliations
  • Inserm (FR)
  • Université de Tours (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Université de Bordeaux (FR)
  • Université Paris Cité (FR)
Corresponding author
Vergès, Bruno
Venue
Cardiovascular Diabetology
Published
2022-11-15
Volume
21
Issue
1
Pages
242-242
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4309438512
Cited by
72
References
101
Citations by year
2026: 26 · 2025: 22 · 2024: 19 · 2023: 5
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion, cc-by)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
GLP-1 receptor agonists, ischemic stroke, stroke prevention, diabetes mellitus, anti-atherosclerotic effects, plaque stability, endothelial function, nitric oxide, vascular smooth muscle cell proliferation, hyperglycemia, hypertension, dyslipidemia, cerebral effects, infarct size, neuroinflammation, oxidative stress, blood-brain barrier permeability, neurogenesis, neuroplasticity, angiogenesis, cerebral perfusion
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hypoglycemic Agents, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. https://app.cochat.ai/papers/10.1186/s12933-022-01686-3
The paper
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022). Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-022-01686-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.